NQO1 and metabolic dysfunction-associated steatohepatitis: Using a mouse model of nonalcoholic steatohepatitis (NASH), Sharma et al.43 showed that pharmacological activation of NRF2, a master regulator of NQO1, decreases TGFβ expression.